A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma

Omar S Usmani, Anu Kemppinen, Elizabeth Gardener, Vicky Thomas, Priyanka Raju Konduru, Christina Callan, Andrew McLoughlin, Vanessa Woodhead, Adam Brady, Elizabeth F Juniper, Peter J Barnes, David Price

Research output: Contribution to journalArticle

8 Citations (Scopus)
5 Downloads (Pure)

Abstract

BACKGROUND: Guidelines recommend reducing treatment in patients with well-controlled asthma after 3 months of stability. However, there is inadequate real-life data to guide physicians on therapy change in daily practice.

OBJECTIVE: To assess asthma control after change to and step-down of fluticasone propionate/formoterol fumarate dihydrate (FP/FOR) in real-life patients.

METHODS: In a randomized controlled, pragmatic, open-label trial, 225 well-controlled patients with asthma were randomized (1:2) to maintain high-dose fluticasone propionate/salmeterol xinafoate (FP/SAL, 1000/100 μg) or switch to FP/FOR (1000/40 μg) daily for 12 weeks (phase 1). One hundred sixteen patients stable on FP/FOR at week 12 were subsequently randomized (1:1) to maintain this therapy, or stepped down to FP/FOR (500/20 μg) daily for 12 weeks (phase 2). The primary end point was the 7-question Asthma Control Questionnaire (ACQ7) score.

RESULTS: In phase 1, FP/FOR (1000/40 μg) (n = 126) was noninferior to FP/SAL (1000/100 μg) (n = 73) for ACQ7 (difference in means, -0.12; 95% CI, -0.32 to 0.09). In phase 2, FP/FOR (500/20 μg) (n = 52) was noninferior to FP/FOR (1000/40 μg) (n = 52) for ACQ7 (difference in means, 0.01; 95% CI, -0.20 to 0.22). There was no significant difference in exacerbation rate between the groups in either phase. However, 1 to 2 exacerbations in 12 months before phase 1 were associated with the occurrence of an exacerbation after step-down (P = .007).

CONCLUSIONS: In patients with well-controlled asthma, a change from FP/SAL to FP/FOR did not compromise asthma control. Step-down of FP/FOR was well tolerated; however, in contrast to current guidelines, our data suggest caution in stepping down patients uncontrolled in the last 12 months. Larger step-down studies are required to confirm these findings.

Original languageEnglish
Pages (from-to)1378-1387.e5
Number of pages10
JournalThe journal of allergy and clinical immunology. In practice
Volume5
Issue number5
Early online date25 Mar 2017
DOIs
Publication statusPublished - Sep 2017

Keywords

  • ACQ7
  • Biomarkers
  • Combination therapy
  • Fluticasone
  • Formoterol
  • Fractional exhaled nitric oxide
  • Inhaled corticosteroids
  • Pragmatic trials
  • Salmeterol
  • Step-down
  • Antiasthmatic agents

Fingerprint Dive into the research topics of 'A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma'. Together they form a unique fingerprint.

  • Cite this

    Usmani, O. S., Kemppinen, A., Gardener, E., Thomas, V., Konduru, P. R., Callan, C., McLoughlin, A., Woodhead, V., Brady, A., Juniper, E. F., Barnes, P. J., & Price, D. (2017). A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma. The journal of allergy and clinical immunology. In practice, 5(5), 1378-1387.e5. https://doi.org/10.1016/j.jaip.2017.02.006